ICU admission for solid cancer patients treated with immune checkpoint inhibitors

Anne-Claire Toffart, Anne-Pascale Meert, Florent Wallet, Aude Gibelin, Olivier Guisset, Frédéric Gonzalez, Amélie Seguin, Achille Kouatchet, Myriam Delaunay, Didier Debieuvre, Boris Duchemann, Gaelle Rousseau-Bussac, Martine Nyunga, David Grimaldi, Albrice Levrat, Elie Azoulay and Virginie Lemiale

ULB Institutional Repository from ULB -- Universite Libre de Bruxelles

Abstract: Background: Immune checkpoint inhibitors (ICI) have revolutionized the management of cancer. They can induce immune-related adverse events (irAE) leading to intensive care unit (ICU) admission. We aimed to describe irAEs for ICU admissions in solid cancer patients treated with ICIs. Methods: This prospective multicenter study was conducted in France and Belgium. Adult patients with solid tumor and treated with systemic ICIs within the last 6 months, requiring non-programmed ICU admission were included. Patients admitted for microbiologically documented sepsis were excluded. Imputability of irAEs in ICU admissions was described according to the WHO-UMC classification system at ICU admission and at ICU discharge. The use of immunosuppressant treatment was reported. Results: 115 patients were eligible. Solid tumor was mainly lung cancer (n = 76, 66%) and melanoma (n = 18, 16%). They were mainly treated with an anti-PD-(L)1 alone (n = 110, 96%). Main ICU admission reasons were acute respiratory failure (n = 66, 57%), colitis (n = 14, 13%), and cardiovascular disease (n = 13, 11%). ICU admission was considered “likely” associated with irAE for 48% (n = 55) of patients. Factors independently associated with irAE were a good ECOG performance status (PS) (ECOG-PS of 0 or 1 vs. ECOG-PS of 2–3, odds ratio [OR] = 6.34, 95% confidence interval [95% CI] 2.13–18.90, and OR = 3.66, 95% CI 1.33–10.03, respectively), and a history of irAE (OR = 3.28, 95% CI 1.19–9.01). Steroids were prescribed for 41/55 (75%) patients with ICU admission “likely” related to irAE. Three patients were subsequently treated with immunosuppressants. Conclusion: IrAEs accounted for half of ICU admissions in cancer patients receiving ICIs. They could be treated with steroids. Identifying the imputability of irAEs in ICU admissions remains a challenge.

Keywords: Immune checkpoint inhibitor; Immune-related adverse event; Intensive care; Solid tumor (search for similar items in EconPapers)
Date: 2023-12
Note: SCOPUS: ar.j
References: View complete reference list from CitEc
Citations:

Published in: Annals of intensive care (2023) v.13 n° 1

Downloads: (external link)
https://dipot.ulb.ac.be/dspace/bitstream/2013/372364/1/doi_356008.pdf Full text for the whole work, or for a work part (application/pdf)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:ulb:ulbeco:2013/372364

Ordering information: This working paper can be ordered from
http://hdl.handle.ne ... lb.ac.be:2013/372364

Access Statistics for this paper

More papers in ULB Institutional Repository from ULB -- Universite Libre de Bruxelles Contact information at EDIRC.
Bibliographic data for series maintained by Benoit Pauwels ().